```html

Iatrogenic Lung Injury (ILI)

Overview

Iatrogenic lung injury (sometimes called “medical‑induced lung injury”) refers to any damage to the lung tissue that occurs as an unintended consequence of medical treatment or intervention. The injury can be acute or evolve over weeks to months, and it may affect a single lung region or involve both lungs.

Who it affects: ILI can occur in patients of any age, but it is most commonly reported in adults undergoing invasive procedures, mechanical ventilation, or receiving certain drugs. The elderly and those with pre‑existing pulmonary disease (e.g., COPD, interstitial lung disease) are particularly vulnerable.

Prevalence: Exact rates are difficult to capture because ILI is often under‑reported, but large studies give a sense of scope:

• Ventilator‑associated lung injury (VALI) occurs in up to 30% of patients who receive mechanical ventilation for >48 hours (NIH, 2022).
• Drug‑induced pulmonary toxicity is reported in 2–5% of patients treated with high‑dose chemotherapy, immune checkpoint inhibitors, or amiodarone (Mayo Clinic, 2023).
• Procedural complications (e.g., bronchoscopy, lung biopsy) cause clinically significant lung injury in <1% of cases, but subclinical injury may be higher when scanned with CT.

While most cases are mild and resolve with supportive care, severe forms can lead to respiratory failure, prolonged hospital stays, and increased mortality.

Symptoms

Symptoms can range from subtle to life‑threatening, often mirroring other lung disorders. Recognizing the pattern in the context of recent medical interventions is key.

Common symptoms

• Shortness of breath (dyspnea): May be sudden after a procedure or develop gradually over days.
• Cough: Usually dry, but can become productive if secondary infection develops.
• Chest pain or discomfort: Often pleuritic (sharp, worsens with breathing).
• Fever: Can indicate inflammation or secondary infection.
• Wheezing or crackles: Detected on auscultation, reflecting airway irritation or fluid.
• Fatigue and malaise: Generalized feeling of being unwell.

Less common or late‑onset symptoms

• Weight loss (especially with drug‑induced interstitial lung disease).
• Night sweats.
• Hypoxia (low oxygen saturation) that may not be obvious without pulse‑oximetry.
• Hemoptysis (coughing up blood) in rare cases of pulmonary hemorrhage.

Causes and Risk Factors

Iatrogenic lung injury results from a spectrum of medical actions. Below are the main categories and associated risk factors.

Mechanical ventilation

• High tidal volumes or pressures → barotrauma.
• Repeated opening/closing of alveoli → volutrauma.
• Oxygen toxicity from FiO₂ >60% for prolonged periods.

Procedural interventions

• Bronchoscopy: Trauma from biopsy, laser, or electrocautery.
• Pleural procedures: Chest tube insertion, thoracentesis causing pneumothorax or hemothorax.
• Radiation therapy: Radiation pneumonitis after 5–20 Gy.

Pharmacologic agents

• Antibiotics (nitrofurantoin, sulfonamides).
• Chemotherapy (bleomycin, cyclophosphamide).
• Targeted & immunotherapy (immune checkpoint inhibitors, EGFR TKIs).
• Cardiac meds (amiodarone, methotrexate).
• Non‑steroidal anti‑inflammatory drugs (rarely).

Other sources

• Blood product transfusion–related acute lung injury (TRALI).
• Contrast‑enhanced imaging with high‑osmolar agents.
• Extracorporeal membrane oxygenation (ECMO) related lung stress.

Risk factors that increase susceptibility

• Age > 65 years.
• Pre‑existing lung disease (COPD, interstitial lung disease, asthma).
• Smoking history.
• Renal or hepatic impairment (affects drug clearance).
• Genetic predisposition (e.g., TPMT deficiency for azathioprine toxicity).
• High cumulative doses of toxic drugs.
• Prolonged or high‑pressure mechanical ventilation.

Diagnosis

Diagnosing ILI is a process of exclusion—ruling out infection, heart failure, or primary lung disease, then linking the timing of symptoms to a medical intervention.

Clinical assessment

• Detailed history focusing on recent surgeries, medications, ventilation settings, and procedures.
• Physical exam: auscultation for crackles, wheezes, decreased breath sounds.

Imaging studies

Test	Typical Findings in ILI
Chest X‑ray	Diffuse infiltrates, atelectasis, pneumothorax, or pleural effusion.
High‑resolution CT (HRCT)	Ground‑glass opacities, crazy‑paving pattern, consolidations, or fibrosis depending on stage.

Laboratory tests

• Arterial blood gases (ABG) – assess hypoxemia, hypercapnia.
• Complete blood count – eosinophilia may suggest drug reaction.
• Serum biomarkers (KL‑6, surfactant protein‑D) helpful in research settings.
• Microbiologic cultures when infection is a concern.

Pulmonary function tests (PFTs)

Used mainly for sub‑acute or chronic ILI to document restrictive patterns and reduced diffusing capacity (DLCO).

Bronchoscopy with bronchoalveolar lavage (BAL)

Helps exclude infection, identify eosinophils, or detect drug‑related cytology. BAL fluid often shows a lymphocyte‑predominant pattern in drug‑induced injury.

Biopsy (trans‑bronchial or surgical)

Reserved for atypical cases where diagnosis remains uncertain. Histology may show organizing pneumonia, diffuse alveolar damage, or interstitial fibrosis.

Treatment Options

Therapy is tailored to the underlying cause, severity, and patient comorbidities.

General supportive measures

• Supplemental oxygen to maintain SpO₂ ≥ 92% (or ≥ 88% in COPD).
• Optimizing ventilator settings: low tidal volume (6 mL/kg ideal body weight), plateau pressure < 30 cm H₂O, and modest FiO₂.
• Fluid management – avoid excessive fluid overload that worsens pulmonary edema.
• Positioning: prone ventilation for severe ARDS improves oxygenation.

Specific therapies

• Corticosteroids: Frequently used for drug‑induced interstitial lung disease, radiation pneumonitis, and acute inflammation. Typical regimen: methylprednisolone 1 mg/kg IV then taper.
• Drug discontinuation: Immediate cessation of the offending agent is critical. In chemotherapy‑induced injury, dose reduction or switching agents may be required.
• Antibiotics/antivirals: Given only if secondary infection is suspected.
• Immunomodulators: In severe immune checkpoint inhibitor pneumonitis, high‑dose steroids plus infliximab or mycophenolate may be used.
• Bronchodilators & mucolytics: Helpful for wheezing and secretions.
• Extracorporeal Life Support (ECLS): ECMO is a rescue option for refractory respiratory failure when conventional ventilation fails.

Lifestyle & rehabilitation

• Pulmonary rehabilitation – supervised exercise, breathing techniques, and education.
• Smoking cessation – smoking dramatically worsens lung healing.
• Vaccinations: influenza, COVID‑19, pneumococcal to prevent superimposed infection.

Living with Iatrogenic Lung Injury

Long‑term management focuses on symptom control, monitoring for progression, and preserving quality of life.

Daily management tips

• Monitor oxygen saturation: Home pulse‑oximeter; seek help if SpO₂ drops below 90%.
• Medication adherence: Take prescribed steroids or other meds exactly as directed. Avoid self‑stopping.
• Stay active within limits: Gentle walking, breathing exercises (pursed‑lip breathing, diaphragmatic breathing).
• Hydration & nutrition: Adequate fluids thin secretions; high‑protein diet supports tissue repair.
• Environmental control: Reduce exposure to pollutants, dust, and allergens.
• Regular follow‑up: Pulmonology appointments every 3–6 months, or sooner if symptoms change.

Psychosocial support

Living with chronic lung injury can be stressful. Consider counseling, support groups, or patient‑education programs offered by hospitals or organizations like the American Lung Association.

Prevention

Because the injury is iatrogenic, many preventive steps involve the healthcare team, but patients can also play a role.

For clinicians

• Employ lung‑protective ventilation strategies (low tidal volume, limited pressures).
• Use the lowest effective oxygen concentration; titrate FiO₂.
• Screen for drug‑specific risk factors before initiating potentially toxic medications.
• Implement protocol‑driven checks for central lines, transfusions, and contrast use to reduce TRALI and contrast‑induced injury.
• Educate patients on signs of early lung toxicity.

For patients & caregivers

• Keep an updated medication list and discuss any new symptoms promptly.
• Ask about alternative drug choices or dose adjustments if you have pre‑existing lung disease.
• Maintain good respiratory hygiene (hand washing, mask use in high‑risk settings).
• Report any worsening dyspnea, fever, or chest pain after a procedure or new medication.

Complications

If ILI is not recognized or managed appropriately, several serious complications may develop.

• Acute Respiratory Distress Syndrome (ARDS): Diffuse alveolar damage leading to severe hypoxemia.
• Pulmonary fibrosis: Permanent scarring that reduces lung capacity.
• Pneumothorax or pneumomediastinum: Air leaks from barotrauma.
• Secondary infection: Ventilator‑associated pneumonia or opportunistic fungal infections.
• Cardiopulmonary failure: May require prolonged ICU stay or ECMO.
• Reduced functional status: Loss of independence, increased fall risk.

When to Seek Emergency Care

References

• National Heart, Lung, & Blood Institute (NHLBI). Ventilator-Associated Lung Injury, 2022.
• Mayo Clinic. Drug-Induced Lung Disease, 2023.
• Cleveland Clinic. Management of Acute Respiratory Distress Syndrome, 2022.
• World Health Organization (WHO). Guidelines on Radiation Safety and Lung Health, 2021.
• American Thoracic Society. Clinical Practice Guidelines for Iatrogenic Pulmonary Complications, 2023.

```